Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
1-Minute Consult

What are the treatment options for myasthenia gravis if first-line agents fail?

Christopher Zust, MD and John A. Morren, MD
Cleveland Clinic Journal of Medicine February 2023, 90 (2) 81-84; DOI: https://doi.org/10.3949/ccjm.90a.22022
Christopher Zust
Staff Neurologist, McLeod Neurological Associates, Florence, SC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John A. Morren
Staff, Neuromuscular Center, and Program Director, Neuromuscular Medicine Fellowship, Neurological Institute, Cleveland Clinic, Cleveland, OH; Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Find this author on Cleveland Clinic
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

    • View popup
    TABLE 1

    Ranking of therapies for acetylcholine receptor antibody-positive generalized myasthenia gravis

    First-linePyridostigmine, prednisone, thymectomya
    Second-lineAzathioprine, mycophenolate mofetil, intravenous immunoglobulin
    Third-lineMethotrexate, tacrolimus,b eculizumab,c ravulizumab,c efgartigimod,c plasmapheresis
    Fourth-lineRituximab, cyclosporineb
    Fifth-lineCyclophosphamide
    • ↵a For certain patients with acetylcholine receptor antibody-positive generalized myasthenia gravis without thymoma (see reference 5).

    • ↵b May be considered as an early treatment option, depending on clinical context.

    • ↵c Newer agents with emerging data; may be considered as early treatment option for refractory acetylcholine receptor antibody-positive generalized myasthenia gravis, but cost may be prohibitive.

    • Based on information in references 5 and 6.

    • View popup
    TABLE 2

    Clinical features of fatigable weakness in myasthenia gravis by region of involvement

    Muscle group/regionManifestation of fatigable weakness in myasthenia gravis
    OcularFluctuating ptosis (often asymmetrical, worsened by sustained upgaze) with or without variable diplopia
    Ptosis may improve with application of an ice pack to the eyes, ie, the bedside ice-pack test
    BulbarDysarthria with or without dysphonia; worse at the end of long conversations, when especially nasal-sounding, “mushy,” or “wet” speech is significant
    Painless dysphagia, which may include nasal regurgitation, sialorrhea, and frequent throat-clearing, with or without coughing; may range from weak to frank choking
    Masticatory or chewing weakness; when severe, the mouth may hang open, and the patient may use a hand to close or manipulate the jaw
    FacialBilateral weakness with “sagging and expressionless” face and a horizontal smile
    Inability to close eyes firmly
    Drooling from poorly sealed lips
    Inability to whistle, pucker lips, or use a straw
    Axial WeakWeak flexion or extension of the neck, “dropped” head when severe
    Occasional stooped posture with anteroposterior truncal flexion (camptocormia) or lateral trunk flexion (“Pisa syndrome”)
    Limb or appendicularWeakness that affects proximal more than distal upper and lower limb groups
    Difficulty getting up from low-seated positions, using arms for overhead activities like washing hair; worse with repeated and sustained actions
    RespiratoryOrthopnea
    Dyspnea on exertion or with increased intra-abdominal pressure as when bending forward to tie shoelaces, or when trunk is immersed in a pool
    Classic features of accessory respiratory muscle use during respiratory distress may be blunted with significant myasthenic weakness of these muscles
    Decreased counts (< 20) on a single-breath counting test suggest significant respiratory muscle weakness and risk for respiratory failure
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 90 (2)
Cleveland Clinic Journal of Medicine
Vol. 90, Issue 2
1 Feb 2023
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
What are the treatment options for myasthenia gravis if first-line agents fail?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
What are the treatment options for myasthenia gravis if first-line agents fail?
Christopher Zust, John A. Morren
Cleveland Clinic Journal of Medicine Feb 2023, 90 (2) 81-84; DOI: 10.3949/ccjm.90a.22022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
What are the treatment options for myasthenia gravis if first-line agents fail?
Christopher Zust, John A. Morren
Cleveland Clinic Journal of Medicine Feb 2023, 90 (2) 81-84; DOI: 10.3949/ccjm.90a.22022
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • FIRST-LINE THERAPY: PYRIDOSTIGMINE
    • MANAGING CORTICOSTEROID THERAPY
    • ASSESSING THERAPEUTIC FAILURE
    • ASSESS FOR MYASTHENIC CRISIS
    • WHEN TO CONSIDER NONSTEROIDAL IMMUNOSUPPRESSIVE THERAPY
    • MONITORING TREATMENT
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Myasthenia gravis: An update for internists
  • Google Scholar

More in this TOC Section

  • Do I need to treat supine hypertension in my hospitalized patient?
  • What diagnostic tests should be done after discovering clubbing in a patient without cardiopulmonary symptoms?
  • Does my adult patient need a measles vaccine?
Show more 1-Minute Consult

Similar Articles

Subjects

  • Neurology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire